Full-Time

Field Services Veterinarian

Posted on 4/30/2025

Deadline 5/28/25
Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

No salary listed

Senior

Sydney NSW, Australia

Category
Veterinary Professionals
Medical, Clinical & Veterinary
Requirements
  • A Veterinary Degree and Registration with the NSW Veterinary Surgeons Board is essential.
  • Minimum 5 years’ experience in clinical companion animal veterinary general or specialty practice
  • Experience with companion animal vaccines and parasiticides; industry experience not essential but preferred
  • Excellent presentation, oral and written communications skills
  • Ability to convey technical information in a manner easily understood
  • Ability to define and implement calendar plans for achievement of aligned metrics including measurement of key performance indicators
  • Competency in MS Office (Word, PowerPoint, Excel)
  • Must be able to work effectively with our customers, stakeholders and sales team
Responsibilities
  • Successfully execute the Field Veterinary Services strategy and action plans to achieve business goals.
  • Liaise with the sales team to develop and implement territory plans for technical field coverage, including customer visits, provision of best practice technical trainings and presentations, and measurement and achievement of defined key team field metrics.
  • Utilise the sales team within territory to influence customers and clients to drive sales and market share growth.
  • Serve as the territory’s technical expert, evaluating regional and individual technical training needs of the sales representatives and coaching sales representatives in technical selling skills.
  • Prepare and deliver technical trainings on products to our veterinary and retail customers and to university and TAFE students.
  • Build and maintain effective working relationships with customers and stakeholders (e.g., veterinarians, vet nurses, store managers, etc).
  • Develop and maintain relationships with key opinion leaders (KOL’s) and key influencers (e.g. specialists, vet schools, key accounts etc).
  • Ensure adoption, best practice use, and value capture of Customer Relationship Management (CRM).
  • Represent the company at Veterinary Schools, Professional Veterinary Associations and Conferences
  • Provide technical advice to veterinarians, veterinary and pet retail staff, and consumers on company products.
  • Develop and implement field materials as determined with marketing and the Field Services Veterinary in consultation with the Technical Services Lead.
  • Develop and implement market development studies and produce publications to support launches and drive portfolio development.
  • Implement formal training programs for the sales teams to measure their competencies.
  • Ensure effective communication across the sales and marketing team, share knowledge and participate positively in sales team meetings and marketing-initiated forums.
  • Monitor market trends, and competitor activities and provide strategic and tactical recommendations to grow company market share.
  • Take ownership of documentation and pharmacovigilance (PV) responsibilities.
Desired Qualifications
  • Post-Graduate qualifications, such as membership of the Australian College, are an advantage.

Merck & Co., Inc. is a global healthcare company that develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology markets. Merck generates revenue through the sale of prescription medicines, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients, as well as professional resources through platforms like Merck Connect and Merck Manuals. What sets Merck apart from its competitors is its strong emphasis on scientific research and its diverse range of healthcare solutions aimed at improving patient outcomes globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's $1 billion investment in a vaccine site boosts U.S. manufacturing capabilities.
  • AI-driven drug discovery platforms improve R&D efficiency and success rates.
  • Digital twins in clinical trials enhance trial designs and personalized medicine approaches.

What critics are saying

  • Merck's mumps vaccine fraud damages reputation and trust in vaccine products.
  • Susonity cosmetics brand may divert focus from core pharmaceutical operations.
  • U.S. manufacturing expansion faces financial risks from changing market conditions.

What makes Merck unique

  • Merck's collaboration with Benchling enhances bioanalytical workflows for vaccine development.
  • Merck's AI initiatives accelerate R&D and reduce software development costs.
  • Merck's investment in mRNA technology opens new treatment avenues beyond vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

Yahoo Finance
Jun 11th, 2025
Benchling Announces Collaboration With Merck On Vaccine Bioanalysis

Unified platform drives bioanalytical capacity, throughput, and efficiency in regulated environment SAN FRANCISCO, June 11, 2025 /PRNewswire/ -- Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a software framework that helps bring Merck's pre-clinical and clinical bioanalytical workflows onto one flexible, fully integrated platform. The collaboration focuses on three key areas: enhancing speed and throughput with automated data capture and integration; streamlining with a unified platform for managing workflows and data across the bioanalytical lifecycle; and maintaining rigorous quality and compliance standards in a regulated bioanalytical setting. "Our work with Merck demonstrates how technology and thoughtful collaboration can help address key scientific needs in bioanalysis," said Sajith Wickramasekara, co-founder and CEO of Benchling. "By focusing on the modern demands of bioanalytical labs, we're delivering an approach that aims to enhance efficiency throughout the vaccine development lifecycle." "Sophisticated data management capabilities are integral to advancing vaccine research and development," said Roy Helmy, Associate Vice President, Regulated Bioanalytics at Merck Research Laboratories. "We're thrilled to collaborate with the team at Benchling on a digital integration that enables our scientists to access, analyze, and harness data insights throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling RD Cloud as their central source of truth for scientific data, analysis, and collaboration

News Channel Nebraska
Jun 4th, 2025
AI Networking Summit Dallas 2025 Breaks Records and Sets the Stage for the Future of AI-Powered Enterprises

Merck's Sean Finnerty was awarded a Community Appreciation Award for sharing how Merck is using AI to speed up and save software development costs.

Personal Care Magazine
May 30th, 2025
Merck reveals launch of Susonity brand for cosmetics

Merck reveals launch of Susonity brand for cosmetics.

MyCentralJersey
May 29th, 2025
NJ drug companies will spend billions to expand in the U.S. Here's what's driving them

Rahway-based drugmaker Merck last month announced plans to spend $1 billion on a vaccine manufacturing site in North Carolina, plus $8 billion on other upgrades by 2028.

Natural News
May 22nd, 2025
Merck's mumps fraud: A 50-year cover-up exposed as vaccine efficacy claims crumble

Merck's mumps vaccine, part of the MMR shots, is confirmed to be far less effective than claimed, with courts acknowledging intentional fraud to maintain monopoly and avoid admitting failure.

INACTIVE